PRL-3抑制剂 | 893449-38-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: PRL-3抑制剂
• 英文名称: 5-[[5-Bromo-2-[(2-bromophenyl)methoxy]phenyl]methylene]-2-thioxo-4-thiazolidinone
• 英文别名: (5E)-5-[[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
• CAS: 893449-38-2
• 化学式: C₁₇H₁₁Br₂NO₂S₂
• 分子量: 485.2
• InChiKey: HXNBAOLVPAWYLT-OVCLIPMQSA-N

物化性质

• 密度：
  1.85±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：>10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  95.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险类别：
  9
• 危险性防范说明：
  P501,P273,P260,P270,P264,P280,P391,P314,P337+P313,P305+P351+P338,P301+P312+P330
• 危险品运输编号：
  3077
• 危险性描述：
  H302,H319,H372,H410
• 包装等级：
  III

文献信息

• [EN] INHIBITORS OF PTP4A3 FOR THE TREATMENT OF CANCER<br/>[FR] INHIBITEURS DE PTP4A3 POUR LE TRAITEMENT DU CANCER
  申请人：LAZO JOHN S

  公开号：WO2016205534A1

  公开（公告）日：2016-12-22

  The invention provides protein tyrosine phosphatase inhibitor compounds, Their pharmaceutical compositions, uses, and methods of use, such as in the treatment of various cancers, and process for making the compounds. Also disclosed is an improved synthesis of protein tyrosine phosphatase inhibitor and precursor compound thienopyridone (5).

  这项发明提供了蛋白酪氨酸磷酸酶抑制剂化合物，它们的药物组合物，用途以及使用方法，例如在治疗各种癌症中的应用，以及制备这些化合物的方法。还披露了一种改进的蛋白酪氨酸磷酸酶抑制剂和前体化合物噻吩吡啶酮（5）的合成方法。
• Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same
  申请人：Ryu Seong Eon

  公开号：US20090042872A1

  公开（公告）日：2009-02-12

  Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity thereof is modulated.

  本文披露了罗丹宁衍生物、其制备方法以及含有相同物质的药物组合物。这些罗丹宁衍生物具有对蛋白磷酸酶（PPase）如PTP1B、Prl-3、LAR、CD45、Cdc25A、Cdc25B、Cdc25C、Yop、PP1和VHR的抑制活性，并可用于预防和治疗PPase引起的疾病，包括自身免疫疾病、糖尿病、糖耐量受损、胰岛素抵抗、肥胖、癌症等，当其抑制活性被调节时。
• Inhibitors of PTP4A3 for the treatment of cancer
  申请人：Lazo John S.

  公开号：US10308663B2

  公开（公告）日：2019-06-04

  The invention provides protein tyrosine phosphatase inhibitor compounds, Their pharmaceutical compositions, uses, and methods of use, such as in the treatment of various cancers, and process for making the compounds. Also disclosed is an improved synthesis of protein tyrosine phosphatase inhibitor and precursor compound thienopyridone (5).

  本发明提供了蛋白酪氨酸磷酸酶抑制剂化合物、其药物组合物、用途和使用方法（如用于治疗各种癌症）以及化合物的制造工艺。本发明还公开了一种改进的蛋白酪氨酸磷酸酶抑制剂和前体化合物噻吩吡啶酮（5）的合成方法。
• PTP4A3 INHIBITOR FOR THE TREATMENT OF CANCER
  申请人：University of Virginia Patent Foundation

  公开号：EP3310355B1

  公开（公告）日：2020-11-11
• INHIBITORS OF PTP4A3 FOR THE TREATMENT OF CANCER
  申请人：Lazo John S.

  公开号：US20180170946A1

  公开（公告）日：2018-06-21

  The invention provides protein tyrosine phosphatase inhibitor compounds, Their pharmaceutical compositions, uses, and methods of use, such as in the treatment of various cancers, and process for making the compounds. Also disclosed is an improved synthesis of protein tyrosine phosphatase inhibitor and precursor compound thienopyridone (5).